AMPH Stock Analysis: Amphastar P | NASDAQ

Injectable Medications, Inhalation Therapies, Nasal Sprays, Active Ingredients

Total Rating 42

Safety 81

Buy Signal 0.00

Drug Manufacturers - Specialty & Generic
Industry Rotation: -9.1

Market Cap: 850M
Avg Turnover: 9.11M

Risk 3d forecast

Volatility47.1%

VaR 5^th Pctl7.83%

VaR vs Median1.01%

Reward TTM

Sharpe Ratio-0.53

Rel. Str. IBD11.8

Rel. Str. Peer Group16.3

Character TTM

Beta0.861

Beta Downside1.143

Hurst Exponent0.503

Drawdowns 3y

Max DD73.41%

CAGR/Max DD-0.37

CAGR/Mean DD-0.62

EPS (Earnings per Share)

EPS CAGR: -8.09%
EPS Trend: -59.3%

Last SUE: 1.63
Qual. Beats: 1

Revenue

Rev. CAGR: 5.23%
Rev. Trend: 75.4%

Last SUE: 0.65
Qual. Beats: 0

Warnings

Choppy

Below Sma 200d

Tailwinds

No distinct edge detected

Seasonality 11.6 years of data

Jan -2.3% 27

Feb -3.1% 27

Mar +0.7% 19

Apr +0.3% 2

May +8.6% 34

Jun +4.5% 30

Jul +0.1% 10

Aug +5.3% 12

Sep -3.6% 31

Oct +1.1% 16

Nov +6.2% 26

Dec -1.3% 11

How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.

Description: AMPH Amphastar P

Amphastar Pharmaceuticals is a U.S.-based bio-pharmaceutical company founded in 1996 and headquartered in Rancho Cucamonga, California, that develops, manufactures, markets, and sells both generic and proprietary injectable, inhalation, and intranasal products, with operations in the United States, China, and France. Its portfolio spans a diverse range of therapeutic areas, including emergency care (BAQSIMI for severe hypoglycemia, naloxone products for opioid overdose, epinephrine injection, and various emergency syringe products), respiratory health (Primatene MIST, Albuterol sulfate, Ipratropium Bromide HFA), anticoagulation (Enoxaparin), anesthesia (lidocaine products), diagnostics (Cortrosyn), and supportive care (Iron sucrose, Phytonadione, Teriparatide). The company also produces active pharmaceutical ingredients (APIs), including recombinant human insulin and porcine insulin.

Amphastar operates a hybrid business model that combines low-margin generic injectable competition with higher-margin proprietary and 505(b)(2)-type specialty products, a structure common among small-cap specialty pharma companies seeking to balance regulatory and pricing risk. Its vertical integration into API manufacturing, particularly insulin, distinguishes it from peers that rely solely on third-party suppliers and helps mitigate supply chain volatility in the generic sterile injectable market.

Headlines to Watch Out For

BAQSIMI faces intensifying competition from rival glucagon nasal sprays
FDA approvals of complex generic injectables drive segment revenue growth
Enoxaparin generic pricing pressure compresses injectable product margins

Piotroski VR-10 (Strict) 6.5

Net Income: 78.5m TTM > 0 and > 6% of Revenue
FCF/TA: 0.09 > 0.02 and ΔFCF/TA 1.82 > 1.0
NWC/Revenue: 50.37% < 20% (prev 56.15%; Δ -5.77% < -1%)
CFO/TA 0.11 > 3% & CFO 184.6m > Net Income 78.5m
Net Debt (474.5m) to EBITDA (179.0m): 2.65 < 3
Current Ratio: 2.40 > 1.5 & < 3
Outstanding Shares: last quarter (44.2m) vs 12m ago -8.11% < -2%
Gross Margin: 47.68% > 18% (prev 50.03%; Δ -2.34% > 0.5%)
Asset Turnover: 43.47% > 50% (prev 44.59%; Δ -1.13% > 0%)
Interest Coverage Ratio: 4.37 > 6 (EBIT TTM 114.3m / Interest Expense TTM 26.1m)

Altman Z'' 3.98

A: 0.21 (Total Current Assets 631.0m - Total Current Liabilities 263.2m) / Total Assets 1.74b
B: 0.40 (Retained Earnings 703.6m / Total Assets 1.74b)
C: 0.07 (EBIT TTM 114.3m / Avg Total Assets 1.68b)
D: 0.79 (Book Value of Equity 768.2m / Total Liabilities 975.6m)
Altman-Z'' = 3.98 = AA

Beneish M -2.94

DSRI: 1.06 (Receivables 144.9m/134.6m, Revenue 730.0m/720.3m)
GMI: 1.05 (GM 50.03% / 47.68%)
AQI: 0.99 (AQ_t 0.42 / AQ_t-1 0.42)
SGI: 1.01 (Revenue 730.0m / 720.3m)
TATA: -0.06 (NI 78.5m - CFO 184.6m) / TA 1.74b)
Beneish M = -2.94 (Cap -4..+1) = A

What is the price of AMPH shares?

As of August 15, 2026, the stock is trading at USD 20.91 with a total of 305,681 shares traded. Over the past week, the price has changed by +0.63%, over one month by +11.19%, over three months by +20.87% and over the past year by -30.78%.

Current recommended Stop Loss: 19.70 (which is 5.8% or 1.4 ATR below the current price).

Is AMPH a buy, sell or hold?

Amphastar P has received a consensus analysts rating of 3.67. Therefore, it is recommended to hold AMPH.

StrongBuy: 2
Buy: 0
Hold: 4
Sell: 0
StrongSell: 0

What are the forecasts/targets for the AMPH price?

Analysts Target Price	22	5.2%

Amphastar P (AMPH) - Fundamental Data Overview as of 14 August 2026

Market Cap USD = 849.9m (849.9m USD * 1.0 USD.USD)
P/E Trailing = 12.1091
P/S = 1.1642
P/B = 1.1247
P/EG = 2.77
Revenue TTM = 730.0m USD
EBIT TTM = 114.3m USD
EBITDA TTM = 179.0m USD
Long Term Debt = 609.6m USD (from longTermDebt, last quarter)
Short Term Debt = 11.3m USD (from shortTermDebt, last quarter)
Debt = 764.6m USD (from shortLongTermDebtTotal, last quarter) + Leases 76.3m
Net Debt = 474.5m USD (calculated: Debt 764.6m - CCE 290.1m)
Enterprise Value = 1.32b USD (849.9m + Debt 764.6m - CCE 290.1m)
Interest Coverage Ratio = 4.37 (Ebit TTM 114.3m / Interest Expense TTM 26.1m)
EV/FCF = 8.66x (Enterprise Value 1.32b / FCF TTM 152.9m)
FCF Yield = 11.54% (FCF TTM 152.9m / Enterprise Value 1.32b)
FCF Margin = 20.94% (FCF TTM 152.9m / Revenue TTM 730.0m)
Net Margin = 10.76% (Net Income TTM 78.5m / Revenue TTM 730.0m)
Gross Margin = 47.68% ((Revenue TTM 730.0m - Cost of Revenue TTM 381.9m) / Revenue TTM)
Gross Margin QoQ = 50.83% (prev 41.08%)
Tobins Q-Ratio = 0.76 (Enterprise Value 1.32b / Total Assets 1.74b)
Interest Expense / Debt = 3.42% (Interest Expense 26.1m / Debt 764.6m)
Taxrate = 23.01% (23.5m / 102.0m)
NOPAT = 88.0m (EBIT 114.3m * (1 - 23.01%))
Current Ratio = 2.40 (Total Current Assets 631.0m / Total Current Liabilities 263.2m)
Debt / Equity = 1.00 (Debt 764.6m / totalStockholderEquity, last quarter 768.2m)
Debt / EBITDA = 2.65 (Net Debt 474.5m / EBITDA 179.0m)
Debt / FCF = 3.10 (Net Debt 474.5m / FCF TTM 152.9m)
Total Stockholder Equity = 776.8m (last 4 quarters mean from totalStockholderEquity)
RoA = 4.68% (Net Income 78.5m / Total Assets 1.74b)
RoE = 10.11% (Net Income TTM 78.5m / Total Stockholder Equity 776.8m)
RoCE = 8.24% (EBIT 114.3m / Capital Employed (Equity 776.8m + L.T.Debt 609.6m))
RoIC = 6.05% (NOPAT 88.0m / Invested Capital 1.46b)
WACC = 5.99% (E(849.9m)/V(1.61b) * Re(9.01%) + D(764.6m)/V(1.61b) * Rd(3.42%) * (1-Tc(0.23)))
Discount Rate = 9.01% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -97.47 | Cagr: -7.74%
[DCF] Terminal Value 77.97% ; FCFF base≈136.6m ; Y1≈156.6m ; Y5≈230.5m
[DCF] Fair Price = 70.38 (EV 3.47b - Net Debt 474.5m = Equity 2.99b / Shares 42.5m; r=8.35% [WACC [floored]]; 5y FCF grow 15.0% → 2.50% )
EPS Correlation: -59.33 | EPS CAGR: -8.09% | SUE: 1.63 | # QB: 1
Revenue Correlation: 75.36 | Revenue CAGR: 5.23% | SUE: 0.65 | # QB: 0
EPS current Quarter (2026-09-30): EPS=0.85 | Chg30d=+6.49% | Revisions=-50% | Analysts=7
EPS current Year (2026-12-31): EPS=2.86 | Chg30d=+9.07% | Revisions=-50% | GrowthEPS=-11.9% | GrowthRev=+3.9%
EPS next Year (2027-12-31): EPS=2.64 | Chg30d=+50.00% | Revisions=-25% | GrowthEPS=+21.7% | GrowthRev=+4.9%
[Analyst] Revisions Ratio: -70% (up=0, down=7)